Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 12/20 | 0.72 |
| ▸ | GPR174 | Q9BXC1 | 9/20 | 0.72 |
| ▸ | GPR34 | Q9UPC5 | 6/20 | 0.72 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.70 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.70 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.70 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.70 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.70 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.70 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.70 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31442365 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL31442370 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL14953735 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL31442542 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL21464913 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL14924219 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL15386593 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL14882712 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL13854646 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL31442348 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| CN-119936223-A | Metabolic marker for diagnosing or monitoring gastric cancer, screening method and application thereof | 武汉迈特维尔医学科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119534874-A | Metabolic marker for auxiliary diagnosis of schizophrenia, construction method and application | 驻马店市第二人民医院(驻马店市精神病医院) | 2025-02-28 | — | — | CN | claimed |
| CN-118425358-A | Use of lipid markers in detection of polycystic ovary syndrome | 北京大学第三医院（北京大学第三临床医学院） | 2024-08-02 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-111077308-B | Serum metabolism marker for tuberculosis drug resistance diagnosis and application thereof | 佛山市第四人民医院(佛山市结核病防治所) | 2023-07-04 | — | — | CN | claimed |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | claimed |
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | claimed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| CN-121164482-A | Metabolic marker for auxiliary diagnosis of schizophrenia, construction method and application | 驻马店市第二人民医院(驻马店市精神病医院) | 2025-12-19 | — | — | CN | disclosed |
| CN-121068784-A | Differential marker based on metabonomics screening and application of differential marker in identifying freeze-thawing meat products | 江南大学 | 2025-12-05 | — | — | CN | disclosed |
| EP-4637812-A1 | HEPATITIS B COMPOSITIONS | GlaxoSmithKline Biologicals S.A. (BE) | 2025-10-29 | — | — | EP | disclosed |
| CN-120668830-A | Biomarker for evaluating osteoporosis and application thereof | 江苏医药职业学院 | 2025-09-19 | — | — | CN | disclosed |
| US-20160030596-A1 | GAS-FILLED STABILIZED PARTICLES AND METHODS OF USE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-02-04 | — | — | US | disclosed |
| US-20140338432-A1 | METHODS OF SEPARATING LIPIDS | WATERS TECHNOLOGIES CORPORATION (US) | 2014-11-20 | — | — | US | disclosed |
| US-8133736-B2 | Methods for detecting or monitoring cancer using LPE as a marker | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133736-B2 | Methods for detecting or monitoring cancer using LPE as a marker | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110059543-A1 | METHODS FOR DETECTING OR MONITORING CANCER USING LPE AS A MARKER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-10 | — | — | US | disclosed |
| US-20110059543-A1 | METHODS FOR DETECTING OR MONITORING CANCER USING LPE AS A MARKER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | P2RY10 3776/4885GPR174 3317/4885GPR34 3199/4885 |
| US-20160030596-A1 | GAS-FILLED STABILIZED PARTICLES AND METHODS OF USE | LIPA, PPARG, LPXN | P2RY10 1649/4885GPR174 1091/4885GPR34 1954/4885 |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | EXOSC5, EXOSC4, EXOSC10 | P2RY10 4135/4885GPR174 4690/4885GPR34 4442/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | P2RY10 1923/4885GPR174 3232/4885GPR34 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.